Drug Profile
HuMab 5B1 targeted amanitin conjugate - MabVax/Heidelberg Pharma AG
Alternative Names: HuMab 5B1-ADC; HuMab 5B1-ATACLatest Information Update: 28 Feb 2021
Price :
$50
*
At a glance
- Originator Heidelberg Pharma AG; MabVax Therapeutics
- Class Antineoplastics; Immunoconjugates; Immunotoxins
- Mechanism of Action RNA polymerase II inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 28 Feb 2021 No recent reports of development identified for research development in Pancreatic-cancer in Germany (Parenteral)
- 28 Feb 2021 No recent reports of development identified for research development in Pancreatic-cancer in USA (Parenteral)
- 06 Jan 2017 Early research in Pancreatic cancer in Germany (Parenteral) before January 2017